Messenger RNA editing in mammals: New members of the APOBEC family seeking roles in the family business

Trends in Genetics

Volumn 19, Issue 4, 2003, Pages 207-216

  Wedekind, Joseph E ^a   Dance, Geoffrey S C ^b   Sowden, Mark P ^a   Smith, Harold C ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; APOLIPOPROTEIN B; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CYTIDINE DEAMINASE; DNA; ENZYME; MESSENGER RNA; NEUROFIBROMIN; PHORBOLIN 1; PHORBOLIN 2; PHORBOLIN 3; PROTEIN; PROTEIN AID; PROTEIN APOBEC; PROTEIN APOBEC 2; PROTEIN APOBEC 3; PROTEIN APOBEC 3A; PROTEIN APOBEC 3B; PROTEIN APOBEC 3C; PROTEIN APOBEC 3D; PROTEIN APOBEC 3E; PROTEOME; RNA; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

CATALYSIS; CELLULAR DISTRIBUTION; DNA RECOMBINATION; DNA SEQUENCE; ENZYME SUBSTRATE COMPLEX; EXPRESSED SEQUENCE TAG; GENE EXPRESSION; GENE REARRANGEMENT; GENETIC VARIABILITY; HUMAN; MAMMAL; MODEL; MULTIGENE FAMILY; NOMENCLATURE; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN RNA BINDING; PSORIASIS; REVIEW; RNA EDITING; RNA SEQUENCE; RNA STRUCTURE; SEQUENCE HOMOLOGY; TISSUE DISTRIBUTION;

MAMMALIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 0345270035     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-9525(03)00054-4     Document Type: Review

References (73)

1. Venter J.C., et al. The sequence of the human genome. Science. 291:2001;1304-1351.
2. Lander E.S., et al. Initial sequencing and analysis of the human genome. Nature. 409:2001;860-921.
3. Smith H.C., et al. A guide to RNA editing. RNA. 3:1997;1105-1123.
4. Grosjean H., Benne R. Modification and Editing of RNA. 1998;ASM Press.
5. Bass B.L. RNA editing by adenosine deaminases that act on RNA. Annu. Rev. Biochem. 71:2002;817-846.
6. Keegan L.P., et al. The many roles of an RNA editor. Nat. Rev. Genet. 2:2001;869-878.
7. Smith H.C., Sowden M.P. Base-modification mRNA editing through deamination-the good, the bad and the unregulated. Trends Genet. 12:1996;418-424.
8. Stuart K., Panigrahi A.K. RNA editing: complexity and complications. Mol. Microbiol. 45:2002;591-596.
9. Tsudzuki T., et al. Comparative analysis of RNA editing sites in higher plant chloroplasts. J. Mol. Evol. 53:2001;327-332.
10. Hirose T., Sugiura M. Involvement of a site-specific trans-acting factor and a common RNA-binding protein in the editing of chloroplast mRNAs: development of a chloroplast in vitro RNA editing system. EMBO J. 20:2001;1144-1152.
11. Lau P.P., et al. Apolipoprotein B mRNA editing is an intranuclear event that occurs posttranscriptionally coincident with splicing and polyadenylation. J. Biol. Chem. 266:1991;20550-20554.
12. Yang Y., et al. Induction of cytidine to uridine editing on cytoplasmic apolipoprotein B mRNA by overexpressing APOBEC-1. J. Biol. Chem. 275:2000;22663-22669.
13. Maquat L.E., Carmichael G.G. Quality control of mRNA function. Cell. 104:2001;173-176.
14. Greeve J., et al. Apolipoprotein B mRNA editing in 12 different mammalian species: hepatic expression is reflected in low concentrations of apoB-containing plasma lipoproteins. J. Lipid Res. 34:1993;1367-1383.
15. Nakamuta M., et al. Complete phenotypic characterization of the apobec-1 knockout mice with a wild-type genetic background and a human apolipoprotein B transgenic background, and restoration of apolipoprotein B mRNA editing by somatic gene transfer of Apobec-1. J. Biol. Chem. 271:1996;25981-25988.
16. Teng B., et al. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science. 260:1993;1816-1819.
17. Mian I.S., et al. Statistical modelling and phylogenetic analysis of a deaminase domain. J. Comput. Biol. 5:1998;57-72.
18. Anant S., Davidson N.O. An AU-rich sequence element (UUUN[A/U]U) downstream of the edited C in apolipoprotein B mRNA is a high-affinity binding site for Apobec-1: binding of Apobec-1 to this motif in the 3′ untranslated region of c-myc increases mRNA stability. Mol. Cell. Biol. 20:2000;1982-1992.
19. Oka K., et al. Tissue-specific inhibition of apolipoprotein B mRNA editing in the liver by adenovirus-mediated transfer of a dominant negative mutant APOBEC-1 leads to increased low density lipoprotein in mice. J. Biol. Chem. 272:1997;1456-1460.
20. Dance G.S.C., et al. Two proteins essential for apolipoprotein B mRNA editing are expressed from a single gene through alternative splicing. J. Biol. Chem. 277:2002;12703-12709.
21. Mehta A., Driscoll D.M. Identification of domains in APOBEC-1 complementation factor required for RNA binding and apolipoprotein B mRNA editing. RNA. 8:2002;69-82.
22. Smith H.C. Apolipoprotein B mRNA editing: the sequence to the event. Semin. Cell Biol. 4:1993;267-278.
23. Mehta A., et al. Molecular cloning of apobec-1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA. Mol. Cell. Biol. 20:2000;1846-1854.
24. Lellek H., et al. Purification and molecular cloning of a novel essential component of the apolipoprotein B mRNA editing enzyme-complex. J. Biol. Chem. 275:2000;19848-19856.
25. Hirano K.I., et al. Targeted disruption of the mouse apobec-1 gene abolishes apolipoprotein B mRNA editing and eliminates apolipoprotein B48. J. Biol. Chem. 271:1996;9887-9890.
26. Burd C.G., Dreyfuss G. Conserved structures and diversity of functions of RNA-binding proteins. Science. 265:1994;615-621.
27. Brennan C.M., Steitz J.A. HuR and mRNA stability. Cell. Mol. Life Sci. 58:2001;266-277.
28. Blanc V., et al. Mutagenesis of apobec-1 complementation factor reveals distinct domains that modulate RNA binding, protein-protein interaction with apobec-1, and complementation of C to U RNA-editing activity. J. Biol. Chem. 276:2001;46386-46393.
29. Anant S., et al. Novel role for RNA-binding protein CUGBP2 in mammalian RNA editing. CUGBP2 modulates C to U editing of apolipoprotein B mRNA by interacting with apobec-1 and ACF, the apobec-1 complementation factor. J. Biol. Chem. 276:2001;47338-47351.
30. Blanc V., et al. Identification of GRY-RBP as an apolipoprotein B RNA-binding protein that interacts with both apobec-1 and apobec-1 complementation factor to modulate C to U editing. J. Biol. Chem. 276:2001;10272-10283.
31. Yamanaka S.M., et al. Apolipoprotein B mRNA editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc. Natl. Acad. Sci. U. S. A. 92:1995;8483-8487.
32. Sowden M., et al. Overexpression of APOBEC-1 results in mooring sequence-dependent promiscuous RNA editing. J. Biol. Chem. 271:1996;3011-3017.
33. Yamanaka S., et al. Hyperediting of multiple cytidines of apolipoprotein B mRNA by APOBEC-1 requires auxiliary protein(s) but not a mooring sequence motif. J. Biol. Chem. 271:1996;11506-11510.
34. Yamanaka S., et al. A novel translational repressor mRNA is edited extensively in livers containing tumors caused by the transgene expression of the apoB mRNA- editing enzyme. Genes Dev. 11:1997;321-333.
35. Qian X. Low expression of the apolipoprotein B mRNA editing transgene in mice reduces LDL but does not cause liver dysplasia or tumors. Arterioscler. Thromb. Vasc. Biol. 18:1998;1013-1020.
36. Kozarsky K.F., et al. Hepatic expression of the catalytic subunit of the apolipoprotein B mRNA editing enzyme ameliorates hypercholesterolemia in LDL receptor-deficient rabbits. Hum. Gene Ther. 7:1996;943-957.
37. Yang Y., et al. Synthesis and secretion of the atherogenic risk factor apoB100 is reduced through TAT-mediated protein transduction of an mRNA editase into hepatocytes. Mol. Pharmacol. 61:2002;269-276.
38. Yang Y., Smith H.C. Multiple protein domains determine the cell type-specific nuclear distribution of the catalytic subunit required for apolipoprotein B mRNA editing. Proc. Natl. Acad. Sci. U. S. A. 94:1997;13075-13080.
39. Sowden M.P., et al. The editosome for cytidine to uridine mRNA editing has a native complexity of 27S: identification of intracellular domains containing active and inactive editing factors. J. Cell Sci. 115:2002;1027-1039.
40. Sowden M.P., Smith H.C. Commitment of apolipoprotein B RNA to the splicing pathway regulates cytidine-to-uridine editing-site utilization. Biochem. J. 359:2001;697-705.
41. Skuse G.R., et al. The neurofibromatosis type I messenger RNA undergoes base-modification RNA editing. Nucleic Acids Res. 24:1996;478-485.
42. Mukhopadhyay D., et al. C→U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme. Am. J. Hum. Genet. 70:2002;38-50.
43. Greeve J., et al. Absence of APOBEC-1 mediated mRNA editing in human carcinomas. Oncogene. 18:1999;6357-6366.
44. Lee R.M., et al. An alternatively spliced form of apobec-1 messenger RNA is overexpressed in human colon cancer. Gastroenterology. 115:1998;1096-1103.
45. Anant S., et al. Apobec-1 transcription in rat colon cancer: decreased apobec-1 protein production through alterations in polysome distribution and mRNA translation associated with upstream AUGs. Biochim. Biophys. Acta. 1575:2002;54-62.
46. Jarmuz A., et al. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics. 79:2002;285-296.
47. Anant S., et al. ARCD-1, an apobec-1-related cytidine deaminase, exerts a dominant negative effect on C to U RNA editing. Am. J. Physiol. Cell Physiol. 281:2001;C1904-C1916.
48. Muramatsu M., et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J. Biol. Chem. 274:1999;18470-18476.
49. Anantharaman V., et al. Comparative genomics and evolution of proteins involved in RNA metabolism. Nucleic Acids Res. 30:2002;1427-1464.
50. Madsen P., et al. Psoriasis upregulated phorbolin-1 shares structural but not functional similarity to the mRNA-editing protein apobec-1. J. Invest. Dermatol. 113:1999;162-169.
51. Sheehy A.M., et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 418:2002;646-650.
52. Anant S., et al. Evolutionary origins of the mammalian apolipoproteinB RNA editing enzyme, apobec-1: structural homology inferred from analysis of a cloned chicken small intestinal cytidine deaminase. Biol. Chem. 379:1998;1075-1081.
53. Dance G.S., et al. Identification of the yeast cytidine deaminase CDD1 as an orphan C→U RNA editase. Nucleic Acids Res. 29:2001;1772-1780.
54. Navaratnam N., et al. Escherichia coli cytidine deaminase provides a molecular model for apoB RNA editing and a mechanism for RNA substrate recognition. J. Mol. Biol. 275:1998;695-714.
55. Revy P., et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell. 102:2000;565-575.
56. Minegishi Y., et al. Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome. Clin. Immunol. 97:2000;203-210.
57. Muramatsu M., et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 102:2000;553-563.
58. Okazaki I.M., et al. The AID enzyme induces class switch recombination in fibroblasts. Nature. 416:2002;340-345.
59. Rada C., et al. AID-GFP chimeric protein increases hypermutation of Ig genes with no evidence of nuclear localization. Proc. Natl. Acad. Sci. U. S. A. 99:2002;7003-7008.
60. Harris R.S., et al. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell. 10:2002;1247-1253.
61. Petersen-Mahrt S.K., et al. AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature. 418:2002;99-104.
62. Yoshikawa K., et al. AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts. Science. 296:2002;2033-2036.
63. Nagaoka H., et al. Activation-induced deaminase (AID)-directed hypermutation in the immunoglobulin Smu region: implication of AID involvement in a common step of class switch recombination and somatic hypermutation. J. Exp. Med. 195:2002;529-534.
64. Liao W., et al. APOBEC-2, a cardiac- and skeletal muscle-specific member of the cytidine deaminase supergene family. Biochem. Biophys. Res. Commun. 260:1999;398-404.
65. Lau P.P., et al. Dimeric structure of a human apolipoprotein B mRNA editing protein and cloning and chromosomal localization of its gene. Proc. Natl. Acad. Sci. U. S. A. 91:1994;8522-8526.
66. Johansson E., et al. Crystal structure of the tetrameric cytidine deaminase from Bacillus subtilis at 2.0 Å resolution. Biochemistry. 41:2002;2563-2570.
67. Betts L., et al. Cytidine deaminase. The 2.3 Å crystal structure of an enzyme: transition-state analog complex. J. Mol. Biol. 235:1994;635-656.
68. Lau P.P., et al. A DnaJ protein, Apobec-1-binding protein-2, modulates apolipoprotein B mRNA editing. J. Biol. Chem. 276:2001;46445-46452.
69. Lau P.P., et al. Two-hybrid cloning identifies an RNA-binding protein, GRY-RBP, as a component of apobec-1 editosome. Biochem. Biophys. Res. Commun. 282:2001;977-983.
70. Yang Y., et al. Partial characterization of the auxiliary factors involved in apolipoprotein B mRNA editing through APOBEC-1 affinity chromatography. J. Biol. Chem. 272:1997;27700-27706.
71. Fugmann S.D., States D.G. Immunology. One AID to unite them all. Science. 295:2002;1244-1245.
72. Honjo T., et al. Molecular mechanism of class switch recombination: linkage with somatic hypermutation. Annu. Rev. Immunol. 20:2002;165-196.
73. Doi T., et al. De novo protein synthesis is required for the activation-induced cytidine deaminase function in class-switch recombination. Proc. Natl. Acad. Sci. U. S. A. 100:2003;2634-2638.